Biocytogen Signs Three-Year Antibody Discovery Pact with Gilead Sciences

Biocytogen Pharma (Beijing) signed an antibody evaluation/option agreement with Gilead Sciences, granting access to Biocytogen’s fully human antibody library aimed at a wide range of therapeutic targets. Over a three-year period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with an option to acquire global rights for promising antibodies. Biocytogen will receive a payment to enable Gilead’s evaluation of antibodies for a specific target, and it will be eligible to receive option exercise fees along with milestone payments for each selected antibody, plus single-digit royalties on net sales. Specific details of the agreement were not disclosed. More details....

Share this with colleagues: